Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada

被引:4
|
作者
Rocheleau, Genevieve [1 ,2 ]
Franco-Villalobos, Conrado [2 ]
Oliveira, Natalia [2 ]
Brumme, Zabrina L. [2 ,3 ]
Rusch, Melanie [4 ]
Shoveller, Jeannie [2 ,5 ]
Brumme, Chanson J. [2 ]
Harrigan, P. Richard [1 ,2 ]
机构
[1] Univ British Columbia, Dept Med, Vancouver, BC, Canada
[2] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada
[3] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada
[4] Vancouver Isl Hlth Author, Victoria, BC, Canada
[5] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada
来源
PLOS ONE | 2017年 / 12卷 / 09期
基金
加拿大健康研究院;
关键词
ANTIRETROVIRAL THERAPY; RISK-FACTORS; ADHERENCE; TUBERCULOSIS; CARE; INDIVIDUALS; PREDICTORS; MUTATIONS; RESPONSES; PROTEASE;
D O I
10.1371/journal.pone.0184848
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Sociodemographic correlates of engagement in human immunodeficiency virus (HIV) care are well studied, however the association with accessing drug resistance testing (DRT) and the development of drug resistance have not been characterized. Between 1996 - 2014, 11 801 HIV patients accessing therapy in British Columbia were observed longitudinally. A subset of 9456 patients had testable viral load; of these 8398 were linked to census data. Sociodemographic (census tract-level) and clinical (individual-level) correlates of DRT were assessed using multivariable General Estimating Equation logistic regression adjusted odds ratios (aOR). The mean number of tests per patient was 2.1 (Q1-Q3; 0-3). Separately, any drug resistance was determined using IAS-USA (2013) list for 5703 initially treatment naive patients without baseline resistance; 5175 were census-linked (mean of 1.5 protease-reverse transcriptase sequences/patient, Q1-Q3; 0-2). Correlates of detecting drug resistance in this subset were analyzed using Cox PH regression adjusted hazard ratios (aHR). Our results indicate baseline CD4 < 200 cells/L (aOR: 1.5, 1.3-1.6), nRTIonly baseline regimens (aOR: 1.4, 1.3 -1.6), and unknown (therapy initiation before routine pVL in BC) baseline pVL (aOR: 1.8, 1.5 - 2.1) were among individual-level clinical covariates strongly associated with having accessed DRT; while imperfect adherence (aHR: 2.2, 1.9- 2.5), low baseline CD4 count (aHR: 1.9, 1.6 -2.3), and high baseline pVL (aHR: 2.0, 1.6 - 2.6) were associated with a higher likelihood of developing drug resistance. A higher median income (aOR: 0.83, 0.77 - 0.89) and higher percentage of those with aboriginal ancestry (aOR: 0.85, 0.76 - 0.95) were census tract-level sociodemographic covariates associated with decreased access to DRT. Similarly, aboriginal ancestry (aHR: 1.2, 1.1 - 1.5) was associated with development of drug resistance. In conclusion, clinical covariates continue to be the strongest correlates of development of drug resistance and access to DRT for individuals. Regions of high median income and high aboriginal ancestry were weak census-level sociodemographic indicators of reduced DRT uptake, however high aboriginal ancestry was the only sociodemographic indicator for development of drug resistance.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] HIV drug resistance testing
    Bartlett, JG
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1999, 8 (05) : 223 - 223
  • [2] HIV resistance testing and detected drug resistance in Europe
    Schultze, Anna
    Phillips, Andrew N.
    Paredes, Roger
    Battegay, Manuel
    Rockstroh, Juergen K.
    Machala, Ladislav
    Tomazic, Janez
    Girard, Pierre M.
    Januskevica, Inga
    Gronborg-Laut, Kamilla
    Lundgren, Jens D.
    Cozzi-Lepri, Alessandro
    AIDS, 2015, 29 (11) : 1379 - 1389
  • [3] HIV-1 drug resistance and resistance testing
    Clutter, Dana S.
    Jordan, Michael R.
    Bertagnolio, Silvia
    Shafer, Robert W.
    INFECTION GENETICS AND EVOLUTION, 2016, 46 : 292 - 307
  • [4] HIV drug resistance testing in pregnancy
    Duryea, Elaine
    Nicholson, Fiona
    Cooper, Sara
    Kitchell, Ellen
    Roberts, Scott
    Rogers, Vanessa
    McIntire, Donald
    Stewart, Robert
    Sheffield, Jeanne
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2015, 212 (01) : S163 - S164
  • [5] Virtual drug resistance testing in HIV
    Dorrell, S
    DRUG DISCOVERY TODAY, 2000, 5 (09) : 384 - 385
  • [6] Testing for HIV-1 drug resistance
    Hanna, GJ
    Caliendo, AM
    MOLECULAR DIAGNOSIS, 2001, 6 (04): : 253 - 263
  • [7] HIV drug resistance testing in Asia - Is it time?
    Sungkanuparph, S.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2012, 16 : E47 - E47
  • [8] HIV drug resistance testing: is the evidence really there?
    Dunn, DT
    Gibb, DM
    Babiker, AG
    Green, H
    Darbyshire, JH
    Weller, IVD
    ANTIVIRAL THERAPY, 2004, 9 (05) : 641 - 648
  • [9] Testing for HIV-1 Drug Resistance
    George J. Hanna
    Angela M. Caliendo
    Molecular Diagnosis, 2001, 6 (4) : 253 - 263
  • [10] HIV drug resistance testing shows promise
    Stephenson, J
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (04): : 309 - 310